|
Age, years
|
51.2 (12.3)
|
|
Male gender, n (%)
|
153 (62.4)
|
|
High education, n (%)†
|
80 (32.7)
|
|
Currently employed, n (%)
|
139 (56.7)
|
|
High income, n (%)‡
|
95 (38.8)
|
|
SRPQ (satisfaction, 1–5)
|
3.2 (0.8)
|
|
Mastery (7–28)
|
20.7 (3.9)
|
|
Comorbidity (SCQ)
|
3.1 (4.3)
|
|
History of depression, n (%)
|
9 (3.7)
|
|
Disease duration, years
|
23.6 (13.3)
|
|
History of any EAM, n (%)
|
78 (31.8)
|
|
History of psoriasis, n (%)
|
20 (8.2)
|
|
History of IBD, n (%)
|
33 (13.5)
|
|
History of uveitis, n (%)
|
44 (18.0)
|
|
NSAID use, n (%)
|
134 (54.7)
|
|
Biological use, n (%)
|
125 (51.0)
|
|
BASDAI (0–10)
|
4.4 (2.3)
|
|
BASFI (0–10)
|
4.2 (2.6)
|
|
Patient global (0–10)
|
4.8 (2.7)
|
|
SF36-PCS (0–100)
|
38.8 (10.8)
|
|
SF36-MCS (0–100)
|
49.2 (12.8)
|
|
HADS-depression (0–21)
|
4.1 (3.7)
|
